Aktienanalyse zu Axsome Therapeutics, Inc. (AXSM)AXSMAxsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Axsome Therapeutics Inc is currently not a strong buy. The current price is $157.14, with a forward P/E ratio of 32.15, indicating high future earnings expectations despite recent losses. The RSI is at 20.615, suggesting the stock is oversold, but the recent performance shows a 5-day change of -6.66% and a year-to-date change of -12.06%, indicating ongoing downward pressure. The main risk is the company's high debt-to-equity ratio of 243.05%, which could impact its financial stability moving forward.

2 analysts cover AXSM: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 209.54.